The Acquired Hemophilia Surveillance (AHS) Project: A Novel Mechanism of Capturing Post-Marketing Safety Information on rFVIIa (NovoSeven®RT) In Acquired Hemophilia

被引：0

作者：

Lentz, Steven R. ^{[1
]}

Tandra, Anand ^{[2
]}

Peters, Tracy J. ^{[1
]}

Cooper, David L. ^{[3
]}

机构：

[1] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA

[2] Hematol Indiana Hemophilia & Thrombosis Ctr, Indianapolis, IN USA

[3] Novo Nordisk Inc, Clin Med & Regulatory Affairs, Princeton, NJ USA

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1508 / 1508

页数：1

共 14 条

[1] A NOVEL MECHANISM OF CAPTURING POST-MARKETING SAFETY INFORMATION ON RECOMBINANT FACTOR VIIA (RFVIIA) IN THE RARE DISORDER ACQUIRED HEMOPHILIA: THE ACQUIRED HEMOPHILIA SURVEILLANCE (AHS) PROJECT
Lentz, S.
Tandra, A.
Doucette, K.
Cooper, D. L.
VALUE IN HEALTH, 2011, 14 (03) : A60 - A60
[2] A Novel Approach to Capturing Post-Marketing Safety Information On Recombinant Factor VIIa (rFVIIa) in Acquired Hemophilia: Final Data From the Acquired Hemophilia Surveillance (AHS) Project
Lentz, Steven R.
Tandra, Anand
Gut, Robert Z.
Cooper, David L.
BLOOD, 2012, 120 (21)
[3] A novel supplemental approach to capturing post-marketing safety information on recombinant factor VIIa in acquired hemophilia: the Acquired Hemophilia Surveillance project
Lentz, Steven R.
Tandra, Anand
Gut, Robert Z.
Cooper, David L.
JOURNAL OF BLOOD MEDICINE, 2014, 5 : 1 - 3
[4] United States Post-Marketing Safety (PMS) Study of rpFVIII in Patients with Acquired Hemophilia A: Preliminary Data
Crea, R.
Huang, Jui-Fu
Bajwa, Naghmana
Gringeri, Alessandro
BLOOD, 2017, 130
[5] Recombinant activated factor VII use for surgical/invasive procedures in congenital haemophilia with inhibitors and acquired hemophilia: analysis from 10-year Japanese post-marketing surveillance
Takedani, H.
Shima, M.
Horikoshi, Y.
Koyama, T.
Fukutake, K.
Kuwahara, M.
Ishiguro, N.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 933 - 933
[6] PISA - safety, immunogenicity and efficacy of a full length DNA rAHF-PMF in patients with hemophilia A in the Italian post-marketing surveillance study
Schino, M.
Rocino, A.
Santagostino, E.
Mazzucconi, M. G.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 535 - 535
[7] Treatment of acute bleeding episodes in acquired haemophilia with recombinant activated factor VII (rFVIIa): analysis from 10-year Japanese post-marketing surveillance
Seita, I
Amano, K.
Higasa, S.
Sawada, A.
Kuwahara, M.
Shima, M.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 119 - 119
[8] Evaluation of the safety and efficacy of recombinant Factor IX (nonacog alfa) in Japanese patients with hemophilia B - The second interim analysis of 304 patients in a post-marketing surveillance study
Amano, Kagehiro
Fukutake, Katsuyuki
Hanabusa, Hideji
Taki, Masashi
Matsushita, Tadashi
Shima, Midori
Sakai, Michio
Yamaguchi, Hiromi
Karumori, Toshiyuki
HAEMOPHILIA, 2014, 20 : 22 - 22
[9] Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study
Kim, Soon Ki
Yoo, Ki Young
Lee, Kun Soo
Hwang, Taiju
Choi, Yong Mook
Choi, Eun Jin
Park, Sang Kyu
JOURNAL OF KOREAN MEDICAL SCIENCE, 2018, 33 (01)
[10] Real world use of B-domain-deleted, porcine-sequence factor VIII (RPFVIII) in patients with acquired hemophilia A (AHA): post-marketing safety (PMS) studies in European Union (EU) and in the United States (US)
Crea, R.
Huang, J. -F.
HAEMOPHILIA, 2018, 24 : 120 - 120

← 1 2 →